OTCMKTS:ABSCF AB Science - ABSCF Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AB Science S.A. Please log in to your account or sign up in order to add this asset to your watchlist. $9.00 0.00 (0.00%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$9.00▼$9.0050-Day Range$9.00▼$9.0052-Week Range$7.25▼$13.95VolumeN/AAverage Volume400 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsHeadlinesShort Interest About AB Science (OTCMKTS:ABSCF) StockAB Science SA operates as a pharmaceutical company. The firm specializes in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Its pipeline includes Masitinib and AB8939. The company was founded by Alain Moussy and Jean-Pierre Kinet on July 11, 2001 and is headquartered in Paris, France.Read More Receive ABSCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AB Science and its competitors with MarketBeat's FREE daily newsletter. Email Address ABSCF Stock News HeadlinesMarch 15, 2023 | finance.yahoo.comAB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CETMarch 13, 2023 | finance.yahoo.comAB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)March 22, 2023 | PressReach (Ad)This Stock Has Room To RunAnalysts believe this stock's product demand could rise quickly in the next few years.February 28, 2023 | finance.yahoo.comAB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & TherapyJanuary 31, 2023 | finance.yahoo.comAB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment BankDecember 29, 2022 | finance.yahoo.comAB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosisDecember 27, 2022 | finance.yahoo.comMasitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in SwitzerlandDecember 22, 2022 | finance.yahoo.comAB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment BankMarch 22, 2023 | PressReach (Ad)This Stock Has Room To RunAnalysts believe this stock's product demand could rise quickly in the next few years.December 13, 2022 | marketwatch.comAB Science Gets Canada Request for Additional Information for Masitinib New Drug SubmissionDecember 13, 2022 | finance.yahoo.comAB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)November 21, 2022 | finance.yahoo.comAB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s DiseaseOctober 10, 2022 | finance.yahoo.comAB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s diseaseSeptember 30, 2022 | finance.yahoo.comAB Science today reports its revenues for the first half of 2022 and provides an update on its activitiesSeptember 14, 2022 | finance.yahoo.comAB Science - Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19September 11, 2022 | reuters.comAB Science SAAugust 25, 2022 | seekingalpha.comAB Science's ALS drug Alsitek gets EMA reviewAugust 24, 2022 | finance.yahoo.comAB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALSJune 26, 2022 | msn.comCorpus Christi Museum of Science and History hosts STEM day for kidsJune 7, 2022 | finance.yahoo.comAB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the peer-reviewed Journal of Asthma and AllergyMay 26, 2022 | finance.yahoo.comAB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALSApril 29, 2022 | finance.yahoo.comAB Science reports its revenues for the year 2021 and provides an update on its activitiesApril 28, 2022 | finance.yahoo.comAB Science announced the continuation of the Phase 2 study evaluating masitinib in combination with isoquercetin in COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)February 28, 2022 | finance.yahoo.comAB Science announces the financing of a 8.5 million dollars through the issuance of convertible bonds with attached warrantsFebruary 24, 2022 | finance.yahoo.comAB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment ALS in Canada and to provide an update on its clinical program in all indicationsFebruary 22, 2022 | finance.yahoo.comAB Science announces the publication of the masitinib positive pivotal Phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & NeuroinflammationFebruary 21, 2022 | finance.yahoo.comAB Science announces that Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of ALS under the Notice of Compliance with Conditions (NOC/c) policySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ABSCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AB Science and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ABSCF CUSIPN/A CIKN/A Webwww.ab-science.com Phone(314) 720-0014FaxN/AEmployees96Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesAlain MoussyChairman & Chief Executive OfficerLaurent GuyChief Financial OfficerChristian FassotteGlobal Chief Medical OfficerVéronique GélébartHead-Clinical Operations & Clinical DevelopmentAlexis BernardHead-Veterinary SalesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Front VenturesOTCMKTS:FFNTFAbacus Health ProductsOTCMKTS:ABAHFAcreageOTCMKTS:ACRHFAcreageOTCMKTS:ACRGFView All Competitors ABSCF Stock - Frequently Asked Questions How have ABSCF shares performed in 2023? AB Science's stock was trading at $9.00 at the beginning of the year. Since then, ABSCF shares have increased by 0.0% and is now trading at $9.00. View the best growth stocks for 2023 here. What is AB Science's stock symbol? AB Science trades on the OTCMKTS under the ticker symbol "ABSCF." How do I buy shares of AB Science? Shares of ABSCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AB Science's stock price today? One share of ABSCF stock can currently be purchased for approximately $9.00. How can I contact AB Science? AB Science's mailing address is 3, Avenue George V, Paris, Ile-de-France 75008. The official website for the company is www.ab-science.com. The company can be reached via phone at (314) 720-0014. This page (OTCMKTS:ABSCF) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.